To further validate the importance of decreased Mgat5 activity and thus low N-glycan branching in the Golgihi subset, we treated activated CD8+ T cells with the Mgat5 inhibitor Phostine PST3.1a, a selective inhibitor of Mgat5 enzymatic activity, which has been shown to have antitumor activity in in vivo models of glioblastoma (51). The gene discussed is CD8A; the disease is glioblastoma.